The geriatric population of the USA is rapidly growing, and estimates indicate that it will comprise one-fourth of the total population by year 2025. These patients make up a significant percentage of those treated for psoriasis; however there is little literature focused on specific cutaneous concerns within the population. Physiologic changes associated with aging, concurrent comorbidities, and polypharmacy can all complicate a clinician’s treatment approach and lead to inadequate management or undertreatment. This chapter hopes to serve as a clinical aid in safely addressing a geriatric patient’s cutaneous needs.
- Geriatric dermatology
This is a preview of subscription content, access via your institution.
Bureau UC. Projected resident population of the United States as of July 1, 2025, middle series. Washington, DC: Population Division; 2002.
Bell LM, Sedlack R, Beard CM, Perry HO, Michet CJ, Kurland LT. Incidence of psoriasis in Rochester, Minn, 1980–1983. Arch Dermatol. 1991;127(8):1184–7.
Wong JW, Koo JY. The safety of systemic treatments that can be used for geriatric psoriasis patients: a review. Dermatol Res Pract. 2012;2012:367475.
Mehta NN, Yu Y, Pinnelas R, et al. Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med. 2011;124(8):775.e1–6.
Armstrong EJ, Harskamp CT, Armstrong AW. Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies. J Am Heart Assoc. 2013;2(2), e000062.
Hugh J, Van Voorhees AS, Nijhawan RI, et al. From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies. J Am Acad Dermatol. 2014;70(1):168–77.
van der Voort EA, Koehler EM, Dowlatshahi EA, et al. Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older: Results from a population-based study. J Am Acad Dermatol. 2014;70(3):517–24.
Coskey RJ. Adverse effects of corticosteroids: I. Topical and intralesional. Clin Dermatol. 1986;4(1):155–60.
du Vivier A, Stoughton RB. Tachyphylaxis to the action of topically applied corticosteroids. Arch Dermatol. 1975;111(5):581–3.
Singh G, Singh PK. Tachyphylaxis to topical steroid measured by histamine-induced wheal suppression. Int J Dermatol. 1986;25(5):324–6.
Grozdev IS, Van Voorhees AS, Gottlieb AB, et al. Psoriasis in the elderly: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2011;65(3):537–45.
Parslew R, Traulsen J. Efficacy and local safety of a calcipotriol/betamethasone dipropionate ointment in elderly patients with psoriasis vulgaris. Eur J Dermatol. 2005;15(1):37–9.
Gould JW, Mercurio MG, Elmets CA. Cutaneous photosensitivity diseases induced by exogenous agents. J Am Acad Dermatol. 1995;33(4):551–73. quiz 574-556.
Bressler R, Bahl JJ. Principles of drug therapy for the elderly patient. Mayo Clin Proc. 2003;78(12):1564–77.
Turnheim K. Drug dosage in the elderly. Is it rational? Drugs Aging. 1998;13(5):357–79.
Flammiger A, Maibach H. Drug dosage in the elderly: dermatological drugs. Drugs Aging. 2006;23(3):203–15.
Boffa MJ. Methotrexate for psoriasis: current European practice. A postal survey. J Eur Acad Dermatol Venereol. 2005;19(2):196–202.
Evans WE, Christensen ML. Drug interactions with methotrexate. J Rheumatol Suppl. 1985;12 Suppl 12:15–20.
Bhutani T, Koo J. A review of the chemopreventative effects of oral retinoids for internal neoplasms. J Drugs Dermatol. 2011;10(11):1292–8.
Falck P, Asberg A, Byberg KT, et al. Reduced elimination of cyclosporine A in elderly (>65 years) kidney transplant recipients. Transplantation. 2008;86(10):1379–83.
Heydendael VM, Spuls PI, Ten Berge IJ, Opmeer BC, Bos JD, de Rie MA. Cyclosporin trough levels: is monitoring necessary during short-term treatment in psoriasis? A systematic review and clinical data on trough levels. Br J Dermatol. 2002;147(1):122–9.
Infliximab. (package Insert). Toronto, Canada 2010.
Ustekinumab. (package insert). Horsham, PA 2011.
Etanercept. (package insert). Thousand Oaks, CA 1998–2011.
Reich K, Langley RG, Lebwohl M, et al. Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. Br J Dermatol. 2011;164(4):862–72.
Adalimumab. (package insert). North Chicago, Ill 2002.
Gottlieb AB, Boehncke WH, Darif M. Safety and efficacy of alefacept in elderly patients and other special populations. J Drugs Dermatol. 2005;4(6):718–24.
Militello G, Xia A, Stevens SR, Van Voorhees AS. Etanercept for the treatment of psoriasis in the elderly. J Am Acad Dermatol. 2006;55(3):517–9.
Menter A, Gordon KB, Leonardi CL, Gu Y, Goldblum OM. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. J Am Acad Dermatol. 2010;63(3):448–56.
Fleischmann R, Baumgartner SW, Weisman MH, Liu T, White B, Peloso P. Long term safety of etanercept in elderly subjects with rheumatic diseases. Ann Rheum Dis. 2006;65(3):379–84.
Galloway JB, Hyrich KL, Mercer LK, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford). 2011;50(1):124–31.
Piaserico S, Conti A, Lo Console F, et al. Efficacy and safety of systemic treatments for psoriasis in elderly patients. Acta Derm Venereol. 2014;94(3):293–7.
Editors and Affiliations
Rights and permissions
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Butler, D.C., Koo, J.Y.M. (2015). Psoriasis Therapy in the Geriatric Population. In: Chang, A. (eds) Advances in Geriatric Dermatology. Springer, Cham. https://doi.org/10.1007/978-3-319-18380-0_5
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-18379-4
Online ISBN: 978-3-319-18380-0
eBook Packages: MedicineMedicine (R0)